ReviewArquivos de gastroenterologia2026
PHARMACOLOGICAL TREATMENTS FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTEGRATIVE REVIEW.
Review in Arquivos de gastroenterologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with Inflammatory Bowel Disease (IBD), fatigue is a debilitating problem and may be associated with sleep disturbance, anxiety, depression, anemia, use of systemic steroids and active phase of the disease. In addition, fatigue also affects the working conditions of these patients, as it is associated with absenteeism and is a reason for time off work, surpassing medical appointments and abdominal pain. Currently, there are no well-established pharmacological therapies for fatigue, making it a subject of growing research interest.
objectiveThis study aimed to conduct an integrative review of pharmacological treatments for fatigue in patients with IBD.
methodsInclusion criteria included full articles published from January 1, 2017 to December 31, 2024. Eligible studies had to include fatigue assessment as a primary objective and discuss pharmacological treatments for fatigue in IBD patients.The databases used were PubMed, Lilacs, SciElo and Cochrane and the descriptors were (inflammatory bowel disease) AND (fatigue) AND (drug therapy).
resultsTotal of 294 studies were identified, of which ten met the inclusion criteria, comprising 2,935 patients (1,664 with Crohn's disease, 1,215 with ulcerative colitis, and 56 with irritable bowel syndrome). Vitamin B12 has not demonstrated efficacy in alleviating fatigue in IBD patients. High doses of oral thiamine reduce fatigue, but studies using a dose of 300 mg/day of thiamine have not shown the same effect. Fatigue symptoms have been reduced with the use of vedolizumab, upadacitinib and modafinil. Studies assessing pharmacological treatments for fatigue in IBD remain limited, and available data are still insufficient. Establishing effective pharmacological therapies for fatigue in these patients may lead to better physical and emotional well-being, enhanced social interactions and employability, and reduced financial burdens associated with fatigue management. Further randomized clinical trials and systematic reviews are necessary to advance the understanding of pharmacological interventions for fatigue in IBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.